Glaxo Tests Cheaper Version of Advair for Emerging Markets
This article is for subscribers only.
GlaxoSmithKline Plc is testing a capsule-based inhaler, suggesting the U.K.’s biggest drugmaker is exploring a cheaper version of its best-selling asthma therapy for emerging markets or to compete with generic versions.
Glaxo completed a 60-patient, mid-stage trial in June comparing its Advair Diskus dry-powder inhaler against the capsule-based version of the drug-device combination, according to a posting on the clinicaltrials.gov website.